Sugi Predict

Sugi Predict / Compounds / SCHEMBL798165

SCHEMBL798165

SCHEMBL798165

CC(C)(C)OC(=O)NCCc1c[nH]c2ccc(O)cc12

nearest known ligand 0.70

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 2/20 0.70
▸ SPR P35270 4/20 0.70
▸ KDM4E B2RXH2 3/20 0.70
▸ ALDH1A1 P00352 2/20 0.70
▸ NPSR1 Q6W5P4 2/20 0.70
▸ CYP2D6 P10635 2/20 0.70
▸ CYP1A2 P05177 1/20 0.70
▸ CYP3A4 P08684 1/20 0.70
▸ MAPT P10636 1/20 0.70
▸ IDO1 P14902 1/20 0.70
▸ HPGD P15428 1/20 0.70
▸ BLM P54132 1/20 0.70
▸ NOTUM Q6P988 1/20 0.70
▸ NQO2 P16083 1/20 0.63
▸ LMNA P02545 1/20 0.61
▸ TDP1 Q9NUW8 1/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ HTR2C P28335 1/20 0.61
▸ KMT2A Q03164 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31077788 1.00 TRPV1 (0.70) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL2534000 0.91 TYR (0.62) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL8613795 0.88 TRPV1 (0.55) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL2544150 0.87 HPGD (0.55) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL7318352 0.87 MTNR1A (0.70) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL8194888 0.87 NOTUM (0.70) TRPV1SPRMAPTNOTUM
SCHEMBL29958743 0.86 SPR (0.58) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL16208899 0.86 SPR (0.58) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL16216347 0.86 SPR (0.58) TRPV1SPRKDM4EALDH1A1NPSR1
SCHEMBL16208898 0.86 SPR (0.58) TRPV1SPRKDM4EALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112358433-B Method for preparing 5-hydroxytryptamine hydrochloride by using enzyme-catalyzed fermentation broth containing 5-hydroxytryptamine 河北维达康生物科技有限公司 2022-03-01 — — CN claimed
CN-112358433-A Method for preparing 5-hydroxytryptamine hydrochloride by using enzyme-catalyzed fermentation broth containing 5-hydroxytryptamine 保定保利瑞合生物科技有限公司 2021-02-12 — — CN claimed
US-20250101038-A1 COMPOUNDS Psylo Pty Ltd (AU) 2025-03-27 — — US disclosed
EP-4452937-A1 COMPOUNDS Psylo Pty Ltd (AU) 2024-10-30 — — EP disclosed
WO-2024008341-A1 SEROTONIN ANALOGUES FOR USE IN TREATING METALLOPTOSIS-ASSOCIATED DISORDERS INSTITUT CURIE (FR) 2024-01-11 — — WO disclosed
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 — — US disclosed
US-11787783-B2 Heparanase inhibitors and use thereof Beta Therapeutics Pty Ltd (AU) 2023-10-17 — — US disclosed
WO-2023115166-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023115166-A1 COMPOUNDS Psylo Pty Ltd (AU) 2023-06-29 — — WO disclosed
WO-2023021112-A1 NOVEL SEROTONIN DERIVATIVES AND THEIR USES FOR TREATING IRON-ASSOCIATED DISORDERS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2023-02-23 — — WO disclosed
CN-112358433-B Method for preparing 5-hydroxytryptamine hydrochloride by using enzyme-catalyzed fermentation broth containing 5-hydroxytryptamine 河北维达康生物科技有限公司 2022-03-01 — — CN disclosed
US-6589953-B2 Treatment of anxiety, depression, aggressiveness, panic attacks, obsessive-compulsive disorders, schizophrenia, suicidal tendency, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease PIERRE FABRE MEDICAMENT (FR) 2003-07-08 — — US disclosed
US-20020061891-A1 Indole derivatives as 5-HT1B and 5-HT1D agonists PEREZ MICHEL (FR) 2002-05-23 — — US disclosed
US-20020004198-A1 Novel anti-infectives SMITHKLINE BEECHAM CORPORATION 2002-01-10 — — US disclosed
US-6277853-B1 FOR TREATMENT OF NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS, MIGRAINES, ALCOHOLISM PIERRE FABRE MEDICAMENT (FR) 2001-08-21 — — US disclosed
US-20010007877-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION 2001-07-12 — — US disclosed
WO-2001034146-A1 NOVEL ANTI-INFECTIVES SMITHKLINE BEECHAM CORPORATION (US) 2001-05-17 — — WO disclosed
WO-1997046525-A1 5-ALKOXY-TRYPTAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS 5-HT1D RECEPTOR AGONISTS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1997-12-11 — — WO disclosed
US-5654431-A EXHIBIT SELECTIVITY TOWARDS 5-HYDROXYTRYPTAMINE RECEPTORS OF BRAIN CELLS ALLELIX BIOPHARMACEUTICALS INC. (CA) 1997-08-05 — — US disclosed
US-5607936-A USEFUL IN TREATMENT OF RESPIRATORY DISEASES MERCK & CO., INC. (US) 1997-03-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250101038-A1 COMPOUNDS NLN, SLC18A2, PYGB TRPV1 911/4885SPR 2043/4885KDM4E 3243/4885
US-20020061891-A1 Indole derivatives as 5-HT1B and 5-HT1D agonists HTR1B, HTR1A, HTR1D TRPV1 164/4885SPR 2488/4885KDM4E 3351/4885
US-20010007877-A1 NOVEL ANTI-INFECTIVES CTSL, MMP8, SERPINB1 TRPV1 2884/4885SPR 2129/4885KDM4E 3343/4885
US-11787783-B2 Heparanase inhibitors and use thereof HPSE, HEXD, ENGASE TRPV1 1915/4885SPR 418/4885KDM4E 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.